Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

sdfgsdfgsdfg

Oct 27, 2026

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

sdfgsdfgsdfg

Oct 27, 2026

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

sdfgsdfgsdfg

Oct 27, 2026

Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown antidepressant potential in dozens of human studies. However, native 5-HTP is impractical as a drug due to poor oral bioavailability and short plasma half-life. No FDA/EMA-approved 5-HTP drug product exists. Evecxia utilizes propriety drug delivery technologies to enable sufficient and sustained 5-HTP exposure, thereby realizing the practical therapeutic potential of 5-HTP and Serotonin Synthesis Amplification.

 

Evecxia has two clinical stage products in development: EVX-101, a gastroretentive sustained-release tablet of 5-HTP and low-dose carbidopa, and EVX-301, a 24-hour 5-HTP infusion.



Evecxia’s lead product EVX-101 is Phase 2-ready. Phase 1 studies found excellent safety and acceptable tolerability. EVX-101 is being developed as adjunctive augmentation therapy for patients with inadequate response to first-line antidepressant monotherapy, e.g., SSRIs. 

 

Initial indications include depression and obsessive-compulsive disorder (OCD). The U.S. patient populations for these indications are estimated at 7 million and 1 million respectively. EVX-301 is being developed for patients hospitalized with suicidal ideation, with a US patient population estimated to be approximately 1 million.



Administered adjunctively, EVX-101 amplifies extracellular serotonin—and hence brain serotonin activity—beyond the effect of a first-line antidepressant, which dozens of clinical depression studies support augment antidepressant efficacy. EVX-101 would be safe, have no abuse potential, have therapeutic potential across mood disorders, and as a tablet be easy to prescribe and administer at home. Thus, EVX-101 could make a large positive impact on depression and mood disorder therapy.



First line treatments currently approved for patients with depression and OCD only provide adequate treatment for approximately 30% of patients. Next-line antidepressants (i.e., atypical antipsychotics) have modest efficacy with metabolic, motoric and endocrine safety concerns. EVX-101 could be a safer, more effective, and scalable next-line treatment for these patients.



Sage Group is seeking licensing/commercialization partners for EVX-101.

Join the Sage Healthcare mailing list

Your subscription could not be saved. Please try again.
Your subscription to the Sage Healthcare Newsletter has been successful.

Subscribe to our newsletter and stay updated.

© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026

Join the Sage Healthcare mailing list

Your subscription could not be saved. Please try again.
Your subscription to the Sage Healthcare Newsletter has been successful.

Subscribe to our newsletter and stay updated.

© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026

Join the Sage Healthcare mailing list

Your subscription could not be saved. Please try again.
Your subscription to the Sage Healthcare Newsletter has been successful.

Subscribe to our newsletter and stay updated.

© 2026. All rights reserved.